These include its single arm design, small sample size, a median follow-up that cannot yet reliably report on survival surrogates in prostate cancer, and heterogeneity in risk factors (e.g., a modest median PSA but numerous patients with involved nodes). This evidence concerns the gene KLK3 and prostate cancer.